Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab vs Bevacizumab + Triamcinolone for Neovascular AMD
NCT00370370Phase 3Unknown
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Nov 2005
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised trial of triamcinolone in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Visual Acuity. Status: unknown.
02
Drugs
triamcinolone
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00370370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00370370.